Takeda's tak-861 phase 2b late-breaking data presentations at sleep 2024 demonstrate clinically meaningful impact of oral orexin agonist in narcolepsy type 1 compared to placebo

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse: 4502/nyse:tak) will present today positive results from its phase 2b trial of tak-861 in narcolepsy type 1 (nt1) as late-breaking data presentations at sleep 2024, the 38th annual meeting of the american academy of sleep medicine and the sleep research society. tak-861 is an investigational oral orexin receptor 2 (ox2r) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall.
TAK Ratings Summary
TAK Quant Ranking